Breaking News

Oscar Pistorius Sentenced to 5 Years in Prison
Tweet TWEET

Portfolio Expansions, Product Data, and Announcements by Healthcare Companies - Research Report on Life Technologies, OncoMed,

Portfolio Expansions, Product Data, and Announcements by Healthcare Companies
   - Research Report on Life Technologies, OncoMed, Halozyme Therapeutics,
                        Infinity, and PTC Therapeutics

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 19, 2013

NEW YORK, December 19, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Life
Technologies Corporation (NASDAQ: LIFE), OncoMed Pharmaceuticals, Inc.
(NASDAQ: OMED), Halozyme Therapeutics, Inc. (NASDAQ: HALO), Infinity
Pharmaceuticals, Inc. (NASDAQ: INFI), and PTC Therapeutics, Inc. (NASDAQ:
PTCT). Today's readers may access these reports free of charge - including
full price targets, industry analysis and analyst ratings - via the links
below.

Life Technologies Corporation Research Report

On December 10, 2013, Life Technologies Corporation (Life Technologies)
announced that the Company has expanded their GeneArt® Algae Engineering
portfolio. According to the Company, the new kits contain features requested
by algae biologists and are designed to make work with algae simpler and
faster. Additionally, the Company stated that the GeneArt® Chlamydomonas
Protein Expression Kits and GeneArt® Synechoccus Protein Expression Kits
contain high-expression vectors capable of driving production of genes of
interest to as much 10% of total cellular protein. Commenting on the release,
Nathan Wood, General Manager and Vice President of Synthetic Biology for Life
Technologies, stated, "By combining high levels of both DNA transformation and
protein expression, the new GeneArt® kits allow investigators to move beyond
basic research into more of a production mode and applied science. These were
features specifically requested by users of our first generation kits, and we
believe these capabilities will help algae biologists advance their field to
level of ease that typifies work with yeast and E. coli." The Full Research
Report on Life Technologies Corporation - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/d5de_LIFE

OncoMed Pharmaceuticals, Inc. Research Report

On December 16, 2013, OncoMed Pharmaceuticals, Inc.'s stock climbed up 21.11%
and closed the day at $28.91 per share. The Company's stock increased by as
much as 23.02% over the past three trading days compared to the Nasdaq
composite which went up by 0.64% during the same three day trading period. The
Full Research Report on OncoMed Pharmaceuticals, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/a95c_OMED

Halozyme Therapeutics, Inc. Research Report

On December 16, 2013, Halozyme Therapeutics, Inc.'s stock went down by 0.15%,
closing the day at $13.08 per share. However, the Company's stock reflected an
increase of 2.27% over the past three-day trading period, compared to the Dow
Jones Industrial Average which went up by 0.26% during the same three-day
trading period. The Full Research Report on Halozyme Therapeutics, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/ea1b_HALO

Infinity Pharmaceuticals, Inc. Research Report

On December 16, 2013, Infinity Pharmaceuticals, Inc.'s stock went down by
1.77%, closing the day at $12.73 per share. For the past three trading days,
the Company's stock went down by 4.36%, compared to the Dow Jones Industrial
Average which went up by 0.26% over the same three-day trading period. The
Full Research Report on Infinity Pharmaceuticals, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/3862_INFI

PTC Therapeutics, Inc. Research Report

On December 12, 2013, PTC Therapeutics, Inc. (PTC Therapeutics) announced the
publication of data in PLOS ONE demonstrating that nonsense mutation Duchenne
muscular dystrophy (nmDMD) patients treated with ataluren experienced an
increase in dystrophin expression. According to the Company, patients with
nmDMD typically experience decreased levels of dystrophin protein, which is
critical to normal muscle function. Commenting on the release, Stuart Peltz,
Ph.D., CEO of PTC Therapeutics, stated, "The results of this Phase 2a study
support ataluren's activity as a dystrophin restoration therapy in nonsense
mutation Duchenne muscular dystrophy patients mediated by ribosomal
read-through of nonsense mutations. These positive findings were the basis for
the progression into a Phase 2b study of ataluren in patients with nmDMD,
which further demonstrated the potential of ataluren to slow the progression
of nonsense mutation DMD as measured by the 6-Minute Walk Test and informed
the design of our ongoing Phase 3 study to confirm the safety and efficacy of
ataluren." The Full Research Report on PTC Therapeutics, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/8e75_PTCT

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.